|Bid||1,400.00 x 0|
|Ask||1,440.00 x 0|
|Day's range||1,401.20 - 1,427.60|
|52-week range||1,280.92 - 2,746.59|
|Beta (5Y monthly)||0.32|
|PE ratio (TTM)||13.06|
|Forward dividend & yield||0.76 (5.47%)|
|Ex-dividend date||17 Nov 2022|
|1y target est||N/A|
I'm seeing so many attractive FTSE 100 bargains out there, it's tough deciding which ones I'd buy today if I had the cash for them all. The post As the FTSE 100 climbs, I’d buy these 3 shares in December appeared first on The Motley Fool UK.
I'm looking for the best FTSE 100 value stocks to buy in December. And I think the sinking GSK share price provides an excellent investing opportunity. The post 3 reasons why GSK’s share price is a brilliant bargain! appeared first on The Motley Fool UK.
(Reuters) -GSK will stop selling its blood cancer drug Blenrep in the United States, it said on Tuesday, in another setback for the British drugmaker's oncology business. The company had said this month that Blenrep had failed the main goal of a key study designed to show it was better than an existing treatment on the market, stoking fears that regulatory approval could be rescinded by the U.S. Food and Drug Administration (FDA). On Tuesday GSK said it has begun the process to withdraw Blenrep's marketing authorisation in the country but would continue trial programmes for the drug, adding that some patients would have the option to enrol for continued access to the treatment.